| Kai Hans Hammerich, MD | |
|
25 Newell Rd Ste D21, Bristol, CT 06010 | |
| (860) 585-6944 | |
| (860) 585-7746 |
| Full Name | Kai Hans Hammerich |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 20 Years |
| Location | 25 Newell Rd Ste D21, Bristol, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639308810 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 56474 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bristol Hospital | Bristol, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bristol Hospital Multi-specialty Group, Inc. | 9032014758 | 114 |
News Archive
New research has found NHS patients admitted to hospital at the weekend with a hip fracture are at no greater risk of death compared to weekdays.
3M announced today that it has acquired CodeRyte Inc., an industry leader in clinical natural language processing (NLP) technology and computer-assisted coding solutions for healthcare outpatient providers.
Waters Corporation introduced today two new mass spectrometers for its Xevo MS platform – the Xevo TQ-S and Xevo G2 QTof – that bring a step change in performance to benchtop mass spectrometry. The product introductions were made at the 58th annual meeting of the American Society for Mass Spectrometry (ASMS).
YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico.
Queen's University Belfast are taking part in a global trial to test whether exercise should be prescribed to treat patients with advanced prostate cancer.
› Verified 4 days ago
| Entity Name | Bristol Hospital Multi-specialty Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649265679 PECOS PAC ID: 9032014758 Enrollment ID: O20031204000960 |
News Archive
New research has found NHS patients admitted to hospital at the weekend with a hip fracture are at no greater risk of death compared to weekdays.
3M announced today that it has acquired CodeRyte Inc., an industry leader in clinical natural language processing (NLP) technology and computer-assisted coding solutions for healthcare outpatient providers.
Waters Corporation introduced today two new mass spectrometers for its Xevo MS platform – the Xevo TQ-S and Xevo G2 QTof – that bring a step change in performance to benchtop mass spectrometry. The product introductions were made at the 58th annual meeting of the American Society for Mass Spectrometry (ASMS).
YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico.
Queen's University Belfast are taking part in a global trial to test whether exercise should be prescribed to treat patients with advanced prostate cancer.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kai Hans Hammerich, MD 25 Newell Rd Ste D21, Bristol, CT 06010-5128 Ph: (860) 585-6944 | Kai Hans Hammerich, MD 25 Newell Rd Ste D21, Bristol, CT 06010 Ph: (860) 585-6944 |
News Archive
New research has found NHS patients admitted to hospital at the weekend with a hip fracture are at no greater risk of death compared to weekdays.
3M announced today that it has acquired CodeRyte Inc., an industry leader in clinical natural language processing (NLP) technology and computer-assisted coding solutions for healthcare outpatient providers.
Waters Corporation introduced today two new mass spectrometers for its Xevo MS platform – the Xevo TQ-S and Xevo G2 QTof – that bring a step change in performance to benchtop mass spectrometry. The product introductions were made at the 58th annual meeting of the American Society for Mass Spectrometry (ASMS).
YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico.
Queen's University Belfast are taking part in a global trial to test whether exercise should be prescribed to treat patients with advanced prostate cancer.
› Verified 4 days ago
Peter Francis Daddario, MD Urology Medicare: Medicare Enrolled Practice Location: 25 Newell Rd Ste D21, Bristol, CT 06010 Phone: 860-585-6944 Fax: 860-585-7746 | |
Michael Alan Fischman, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 8 Collins Rd, Bristol, CT 06010 Phone: 860-585-6944 Fax: 860-585-7746 | |
Ariel Morley, PA Urology Medicare: Accepting Medicare Assignments Practice Location: 15 Riverside Avenue, Bristol, CT 06010 Phone: 833-424-3627 |